← All trials
NCT00002819
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 1996
- Primary completion
- Feb 1, 2000
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Gynecologic Oncology GroupLead sponsor
- Loyola UniversityStudy chair
- Tufts UniversityStudy chair
- Franklin Square Hospital CenterStudy chair
- State University of New York, SyracuseStudy chair
- National Cancer Institute (NCI)Collaborator
- Eastern Cooperative Oncology GroupCollaborator
- Southwest Oncology GroupCollaborator
- Cancer and Leukemia Group B (CALGB)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.